Cinanserin hydrochloride (Synonyms:SQ 10643)
目录号 : KM5365 CAS No. : 54-84-2 纯度 : 98%

Cinanserin hydrochloride (SQ 10643) 是一种有效,选择性和高度亲和力的 5-HT2 受体拮抗剂,Ki 为 41 nM。Cinanserin hydrochloride 对 5-HT2 的结合亲和力比对 5-HT1 受体 (Ki 为 3500 nM) 的结合亲和力高得多。Cinanserin hydrochloride 还是严重急性呼吸系统综合症冠状病毒的 3C 样蛋白酶 (3C-like proteinase) 的抑制剂,可大大减少体外的病毒复制。

规格 价格 是否有货 数量
10mg
In-stock
50mg
In-stock
100mg
In-stock
200mg 询价 In-stock
500mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT2 receptor antagonist with a Ki of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT2 than for the 5-HT1 receptor (Ki of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

体外研究

Cinanserin/Cinanserin hydrochloride have binding affinity to SARS-CoV 3CL, HCoV-229E 3CL, with the KD values of 49.4 μM/78.0 μM for SARS-associated coronavirus (SARS-CoV) 3CL and 18.2 μM/36.6 μM for human coronavirus 229E (HCoV-229E) 3CL.
The IC50 values of Cinanserin and Cinanserin hydrochloride for inhibiting the catalytic activity of SARS-CoV 3CL are calculated as 4.92 μM and 5.05 μM, respectively, The corresponding IC50 values for HCoV-229E 3CL are 4.68 μM and 5.68 μM. None of the compounds have inhibitory activity against HRV-14 3C at concentrations up to 200 μM.

体内研究

Cinanserin (5 mg/kg; intravenous injection; for 2 hours; male Wistar rats) treatment significantly reduces systemic burn edema to shamburn levels. Leukocyte-endothelial interactions are significantly reduced by administration of Cinanserin.

Animal Model: Male Wistar rats (250 g) underwent thermal injury
Dosage: 5 mg/kg
Administration: Intravenous injection; for 2 hours
Result: Significantly reduced systemic burn edema to shamburn levels..
分子式
C20H24N2Os.HCl
分子量
376.94
CAS号
54-84-2
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 125 mg/mL (331.62 mM; Need ultrasonic)

H2O : 100 mg/mL (265.29 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6529 mL 13.2647 mL 26.5294 mL
5 mM 0.5306 mL 2.6529 mL 5.3059 mL
10 mM 0.2653 mL 1.3265 mL 2.6529 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.52 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.52 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.52 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号